** Drug developer Jasper Therapeutics' JSPR.O shares fall 70.7% to $1.98 premarket
** Company says its experimental drug, briquilimab, achieved a complete response at week 12 in an early-stage study to treat a skin condition called chronic spontaneous urticaria (CSU)
** But the results were affected by an issue with one specific drug product lot
** CSU causes red, itchy bumps on the skin that come and go without a clear reason
** Company says it halted the drug's asthma trial due to the same drug product lot issue
** In the 10 patients with CSU who received the problematic drug product lot, reduction in mean tryptase levels, a marker of mast cell activity, was lower than expected and there was no noticeable improvement, company says
** Jasper is investigating the issue and expects results in the coming weeks
** As of last close, stock down 68.33% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。